BridgeMD
Alkaline Phosphatase as treatment of Ischemia Reperfusion Injury to prevent delayed graft function or APhIRI II
EU CTIS ID: 2024-515480-66-01
What this study is testing
To study whether exogenous alkaline phosphatase can prevent ischemia reperfusion injury in deceased donor kidney transplantation and will thereby decrease the duration of delayed graft function (DGF). DGF is defined as the need for dialysis that started within 7 days post-transplant, excluding single sessions for hyperkalemia.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients recipients of a donor awaiting cardiac death on the intensive care (definition of a donor cardiac death type III according to the ‘Maastricht classification’)
- Age >18
- Can give written informed consent
You likely can't join if
- Strict vegetarians
- Vegans
- History of allergy to bovine proteins
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.